Abstract
Aim:In our previous report, we identified roles of CLDN7 in regulation of cell signaling. The goal of this study was to identify proteins interacting with CLDN7 in ovarian cancer.Methods:The yeast two-hybrid system was used to identify proteins directly interacting with CLDN7 and cell survival was tested using colony formation assay.Results:Amyloid precursor-like protein 2 (APLP2) was found directly associated with CLDN7 in ovarian cancer cell line OVCA420. In addition, APLP2 showed increased expression in ovarian cancer cell lines and tumor tissue samples compared with non-neoplastic ovarian tissues. Knockdown of CLDN7 led to increased expression of APLP2 at both the mRNA and protein levels. Knockdown of APLP2 was associated with decreased cell survival in ovarian cancer cells.Conclusion:We show a direct interaction of CLDN7 with APLP2. These findings suggest novel regulatory role for APLP2 in ovarian cancer, a role that appears to be mediated by CLDN7.
Highlights
ObjectivesWe identified roles of CLDN7 in regulation of cell signaling
Split ubiquitin membrane-based yeast two-hybrid system identified 30 protein interacting with CLDN7 Transformation of human kidney cDNA library in NMY51 cells expressing the bait vector, followed by growth on selective media identified 30 proteins interacting with CLDN7 (Table 1)
Since amyloid precursor-like protein 2 (APLP2) was identified in our yeast two-hybrid screen, we decided to focus on APLP2 for further study
Summary
We identified roles of CLDN7 in regulation of cell signaling. The goal of this study was to identify proteins interacting with CLDN7 in ovarian cancer. The aim of the current study was to find interacting partner(s) of CLDN7 in ovarian cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
